THE TGF(BETA)-MIR200-MIG6 PATHWAY AND ITS USE IN THE TREATMENT OF CANCER AS AN INDICATOR OF RESISTANCE TO EGFR INHIBITORS

摘要

The present invention provides methods for identifying the susceptibility of a cancer cell or population of cells to treatment with Epidermal Growth Factor (EGF) Tyrosine Kinase Inhibitors (TKIs), such as erlotinib. Methods for the in vitro diagnosis of the susceptibility of a tumor in a subject to treatment with TKIs and monitoring tumor susceptibility during treatment are also provided.